1 / 21

Safe Handling of Hazardous Drugs

Safe Handling of Hazardous Drugs. Dr. Irene Weru, Mpharm (Clinical Pharmacy) Senior Pharmacist – Oncology Services, KNH. Objectives. To discuss current trends in safe handling Highlight Standards available Highlight some recommendations. Introduction. Exposure Opportunity is Increasing.

akio
Télécharger la présentation

Safe Handling of Hazardous Drugs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Safe Handling of Hazardous Drugs Dr. Irene Weru, Mpharm (Clinical Pharmacy) Senior Pharmacist – Oncology Services, KNH

  2. Objectives • To discuss current trends in safe handling • Highlight Standards available • Highlight some recommendations KNH Oncology Symposium 13th April, 2012

  3. Introduction KNH Oncology Symposium 13th April, 2012

  4. Exposure Opportunity is Increasing WHO estimates a 50% increase in cancer patients in the next 20 years Use of drugs for non-malignant diseases (RA, SLE) Anti-viral agents for HIV and other viral illnesses Investigational (IND) Drug Development / Clinical Trials Use of previously banned medicines KNH Oncology Symposium 13th April, 2012

  5. Definition of Hazardous Drugs Carcinogenic Teratogenic Reproductive toxicity Organ toxicity at low doses Genotoxic Structure or toxicity similar to drugs classified as hazardous (NIOSH, 2004) KNH Oncology Symposium 13th April, 2012

  6. Cancer Risk in Workers Leukemia in nurses (Skov et al, 1992) Cyclophosphamide (Sessink et al, 1993)(1.4-10 excess cases/million) NHL & skin cancer (Hansen & Olsen, 1994) Overall increased cancer risk(Martin, 2005 KNH Oncology Symposium 13th April, 2012

  7. Reproductive Risks in Workers Fetal abnormalities (Hemminki et al, 1985) Spontaneous Abortions (Stucker, 1990) Infertility (Valanis et al, 1997 ; Fransman, 2007) Miscarriages (Valanis et al, 1999) KNH Oncology Symposium 13th April, 2012

  8. Teratogenicity Conflicting opinion on exposure during 2nd and 3rd trimesters Greatest danger during 1st trimester Case control study of Finish oncology nurses actively handling chemotherapy during 1st trimester demonstrated statistically significant increase in risk for malformations Hemminki K, Kyyronen P, Lindbohm ML. J Epidemiol Community Hlth 1985 KNH Oncology Symposium 13th April, 2012

  9. Modes of Contact for Drug Exposure Dermal Direct contact Contaminated surfaces Ingestion Food, gum Hand-to-mouth Inhalation Aerosols Vapors Injection Sharps Breakage KNH Oncology Symposium 13th April, 2012

  10. Standards KNH Oncology Symposium 13th April, 2012

  11. Guidelines on hazardous drugs • American society of health system pharmacists • 1985,1990 • 2005: guidelines on handling hazardous drugs • http://www.ashp.org/bestpractices/new/HD-Prepub-final.pdf • NIOSH (National Institute of Occupational Safety and Health) • 2004:NIOSH Hazardous Drug Alert • Appendix A: Sample list • http://www.cdc.gov/niosh/docs/2004-165/ • ISOPP Standards International Society of Oncology Pharmacy Practitioners • OSHA (Occupational Safety and Health Administration) • 1986 • 1995: Controlling Occupational Exposure to Hazardous Drugs • http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html • USP <797> United States Pharmacopeia (USP) KNH Oncology Symposium 13th April, 2012

  12. ISOPP* Standards of Practice Know Your Risk Staff Training Levels of Protection *ISOPP =International Society of Oncology Pharmacy Practice J Onc Pharm Pract 2007; 13 Suppl. KNH Oncology Symposium 13th April, 2012

  13. Training Must include at least: Use of engineering controls use of PPE Preparation Transport Administration Disposal Management of spills Management of acute exposure KNH Oncology Symposium 13th April, 2012

  14. Levels of Protection – Top to bottom Level 1 – Elimination/substitution/replacement Level 2 – Isolation of the hazard/source containment Level 3 – Engineering controls/Proper ventilation Level 3b – Administrative controls/ Organization measures Level 4 – Personal protective equipment (PPE) 14 KNH Oncology Symposium 13th April, 2012

  15. Safety work Benches • Biological safety cabinets (Ventilated Cabinets) KNH Oncology Symposium 13th April, 2012

  16. Isolators KNH Oncology Symposium 13th April, 2012

  17. Personal Protective Equipment Overall/Protective gown • Used for: compounding, administration, spill control, waste management • Closed up to neck • Long sleeves with close-fitting cuffs • Lint free • Liquid repellent • Single-use KNH Oncology Symposium 13th April, 2012

  18. Recommendations & Current Trends KNH Oncology Symposium 13th April, 2012

  19. Monitoring HCW • Reproductive and General Health • Physical Examination • CBC, Urinalysis, LFTs KNH Oncology Symposium 13th April, 2012

  20. Conclusion • The world has moved from the bedside to CSTD KNH Oncology Symposium 13th April, 2012

  21. KNH Oncology Symposium 13th April, 2012

More Related